Loading data
RERENYSE
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Research and development expense | 34.88 m USD | — | — | — |
| Operating profit | 65.23 m USD | 3.97 m USD | -24.41 m USD | -380.39 m USD |
| Interest expense | 863 k USD | 2.06 m USD | 994 k USD | 894 k USD |
| Income tax expense | 8.12 m USD | -7.79 m USD | -5.99 m USD | -16.21 m USD |
| Net income (reported basis) | 48.09 m USD | -1.13 m USD | -22.01 m USD | -357.82 m USD |
| Net income attributable to common shareholders | — | — | -22.01 m USD | -357.82 m USD |
| Basic earnings per share | 0.3 USD/share | -0.01 USD/share | -0.14 USD/share | -2.2 USD/share |
| Diluted earnings per share | 0.3 USD/share | -0.01 USD/share | -0.14 USD/share | -2.2 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.